402 related articles for article (PubMed ID: 35592330)
21. Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2.
Lee KM; Lin SJ; Wu CJ; Kuo RL
Biomed J; 2023 Feb; 46(1):70-80. PubMed ID: 36642222
[TBL] [Abstract][Full Text] [Related]
22. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
[TBL] [Abstract][Full Text] [Related]
23. Advances in COVID-19 mRNA vaccine development.
Fang E; Liu X; Li M; Zhang Z; Song L; Zhu B; Wu X; Liu J; Zhao D; Li Y
Signal Transduct Target Ther; 2022 Mar; 7(1):94. PubMed ID: 35322018
[TBL] [Abstract][Full Text] [Related]
24. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
25. Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective.
Labouta HI; Langer R; Cullis PR; Merkel OM; Prausnitz MR; Gomaa Y; Nogueira SS; Kumeria T
Drug Deliv Transl Res; 2022 Nov; 12(11):2581-2588. PubMed ID: 35290656
[TBL] [Abstract][Full Text] [Related]
26. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
27. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
28. Perspectives and Prospects on mRNA Vaccine Development for COVID-19.
Jin L; Han Z; Zhao P; Sun K
Curr Med Chem; 2022; 29(23):3991-3996. PubMed ID: 35170403
[TBL] [Abstract][Full Text] [Related]
29. mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.
Chen P; Shi X; He W; Zhong G; Tang Y; Wang H; Zhang P
Hum Vaccin Immunother; 2022 Dec; 18(1):2040330. PubMed ID: 35321627
[TBL] [Abstract][Full Text] [Related]
30. Introduction to RNA Vaccines Post COVID-19.
Kramps T
Methods Mol Biol; 2024; 2786():1-22. PubMed ID: 38814388
[TBL] [Abstract][Full Text] [Related]
31. mRNA vaccines: the most recent clinical applications of synthetic mRNA.
Kwon S; Kwon M; Im S; Lee K; Lee H
Arch Pharm Res; 2022 Apr; 45(4):245-262. PubMed ID: 35426547
[TBL] [Abstract][Full Text] [Related]
32. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
[TBL] [Abstract][Full Text] [Related]
33. mRNA vaccines for COVID-19 and diverse diseases.
Hussain A; Yang H; Zhang M; Liu Q; Alotaibi G; Irfan M; He H; Chang J; Liang XJ; Weng Y; Huang Y
J Control Release; 2022 May; 345():314-333. PubMed ID: 35331783
[TBL] [Abstract][Full Text] [Related]
34. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731
[TBL] [Abstract][Full Text] [Related]
35. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
36. A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine.
Walter T; Connor S; Stedman C; Doogue M
Br J Clin Pharmacol; 2022 Mar; 88(3):1385-1386. PubMed ID: 34423463
[No Abstract] [Full Text] [Related]
37. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
[No Abstract] [Full Text] [Related]
38. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
Leav B; Straus W; White P; Leav A; Gaines T; Maggiacomo G; Kim D; Smith ER; Gurwith M; Chen RT;
Vaccine; 2022 Aug; 40(35):5275-5293. PubMed ID: 35753841
[TBL] [Abstract][Full Text] [Related]
39. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study.
McKeigue PM; McAllister DA; Hutchinson SJ; Robertson C; Stockton D; Colhoun HM
Lancet Respir Med; 2022 Jun; 10(6):566-572. PubMed ID: 35227416
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates.
Wu Y; Zhang H; Meng L; Li F; Yu C
Front Immunol; 2022; 13():906457. PubMed ID: 35663946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
